BioCentury
ARTICLE | Financial News

Teva submits thrice-weekly Copaxone sNDA, beats Street

May 3, 2013 12:23 AM UTC

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) disclosed on a conference call to discuss its 1Q13 earnings that it submitted an sNDA to FDA in March to add a thrice-weekly 40 mg dose of Copaxone glatiramer to the label for the multiple sclerosis drug. Teva already markets once-daily 20 mg Copaxone to treat relapsing-remitting MS (RRMS) in the U.S. and shares European rights with Sanofi (Euronext:SAN; NYSE:SNY). ...